Omnicell, Inc. (OMCL) vs SOPHiA GENETICS SA (SOPH)
Omnicell, Inc. and SOPHiA GENETICS SA are both Health Information Services companies. Omnicell, Inc. is the larger, with a market value of $1.5B against $703.2M — 2.1× the size. SOPHiA GENETICS SA has negative trailing earnings, so its P/E is not meaningful; Omnicell, Inc. trades at 39.5×. SOPHiA GENETICS SA grew revenue faster over the last twelve months: 23.7% against 8.45%. Omnicell, Inc. has the higher net margin (3.13% vs −93.9%) and the higher return on invested capital (3.10% vs −196.5%). Across the 19 metrics below, Omnicell, Inc. leads on 13 and SOPHiA GENETICS SA on 6.
Valuation
Profitability
| Metric | OMCL | SOPH | Health Information Services median |
|---|---|---|---|
| Gross margin | 44.77% | 66.63% | 63.38% |
| Operating margin | 4.65% | (85.55%) | (8.35%) |
| Net margin | 3.13% | (93.86%) | (14.70%) |
| Free cash flow margin | 10.17% | (47.83%) | 0.58% |
| Return on equity | 3.06% | (101.22%) | (6.82%) |
| Return on assets | 1.89% | (43.02%) | (6.02%) |
| Return on invested capital | 3.10% | (196.45%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack